Caeregen Therapeutics has been awarded a $1.4 million phase 2 Small Business Innovation Research grant for the development of CTR-107 for the treatment of retinal-related vision loss due to inherited and age-related diseases.
Caeregen will use the grant from the NIH and the National Eye Institute to build on prior research that “demonstrated production feasibility, safety/tolerability, modulation of target gene expression in vitro, and in vivo functional activity,” according to a press release.
CTR-107 (Noregen), initially in development for the treatment of familial exudative